Background: The European Union (EU) has harmonized legislation on pharmaceutical products to implement the single market in this field. European consumers are offered with high quality and safe products that have been brought onto the market through harmonized procedures. The aim of the study was to find out if there still were legislative restrictions to purchasing prescription only medicines (POMs) for personal use from another EU member state. Methods: The medicines authorities in the EU were inquired about the possibilities of a citizen to obtain POMs for personal use from another EU country. The method used was a questionnaire covering both the delivery of foreign prescriptions and import of prescription-only medicines. The questionnaire was mailed, emailed or faxed to the national medicines authorities. Results: An answer was obtained from 11 of the 15 member states. The results showed that the delivery of foreign prescriptions was regulated only in the Nordic countries. All the countries reported prohibitions on delivering prescriptions for drugs that act on the central nervous system and prescriptions that were suspicious. The personal import of drugs was restricted as to the amounts and reimbursement policy. Conclusions: The import of drugs for personal use is not yet comparable to other consumables in the EU. The prevailing restrictions contravene the community legislation and this problem has not yet been solved. It is probable that problems will arise in the near future when information technology is likely to be used increasingly in the delivery of drugs.
The legislative harmonization of the European pharmaceutical market aims at providing consumers with safe, high quality and effective products at a reasonable price whilst ensuring competitiveness and profits to the European pharmaceutical (especially the research-based) industry. 1, 2 Common procedures in the authorization of a drug set time limits and decrease costs due to the avoidance of double work, which is beneficial to both society and industry. 1, 2 Despite the harmonization, national legislations are not yet uniform and differences in treatment, cultural backgrounds and the economic situations of the member states can effect the markets. For example, the prices and classifications of pharmaceuticals still vary for various country-specific reasons. In practice, the harmonization of the European pharmaceutical markets involves commonly shared regulations for the production chain of a drug product starting from the development and manufacturing phase in factories through the authorization procedures, from wholesalers to pharmacies and finally to end-users, the consumers. [1] [2] [3] The harmonization of this chain guarantees a uniform quality of the products, but does it bring something else to the consumers? Can they for example purchase their drugs wherever they wish for such reasons as lower prices or easier availability? According to our results they cannot. The true harmonization of the European pharmaceutical markets, requires at least two elements. First, the acceptance of foreign prescriptions for prescription only medicines (POM), and second the option to import pharmaceuticals from another EU country. The EU policy-making institution, the Commission, has shown a positive attitude to the recognition of foreign prescriptions in its response to two written questions made by members of the European Parliament in 1996 and 1997. 4, 5 The former Commissioner for Industry, Martin Bangemann and Internal Market Commissioner Mario Monti were in favour of the mutual recognition of European prescriptions, except in cases where the order was for drugs affecting the central nervous system or the authenticity of the prescription was suspicious. So far no Community regulations exist on the acceptance of foreign prescriptions although the European Council invited the Commission to study the policy in the member states. 6 In 1999 an empirical study was carried out on delivery of foreign phenoximethylpenicillin prescriptions, which showed that most EU countries accepted foreign European prescriptions, at least when a moderately harmless drug was prescribed. 7 EU legislation allows import of drugs for personal use. The European Court of Justice issued two preliminary rulings EUROPEAN JOURNAL OF PUBLIC HEALTH 2002; 12: 244-248 regarding this subject in 1987 and 1992. 8,9 According to these rulings, drugs do not have to be purchased within the area of one EU country nor has the prescribing doctor to be within the same country. These rulings involved interpretation of Community law, as the legislative framework gave no answer. These rulings, although called preliminary, are binding as Community law is superior to national law. The two preliminary rulings are especially current today. The use of information technology (IT), especially the Internet, for the delivery of drugs is the focus of the European Commission as one central topic among e-commerce issues. 10,11 IT is not limited by national boarders and its rapidly increasing use makes it possible to exploit the opportunities that the single market offers. 12 Pharmacists all over Europe are setting web sites, mainly for advertising purposes. Purchase of pharmaceuticals via the Internet, in other words the online pharmacy, is already possible in some countries, for example in the UK and the Netherlands. Use of electronic prescriptions, i.e. transfer of a prescription from a doctor to a traditional pharmacy via computer connections is still rare (and does not happen to online pharmacies). The USA is far ahead in the use of online pharmacies but also suffers from problems related to them (a major concern is illegal online pharmacies). US online pharmacies verify the authenticity of prescriptions in such traditional ways as requiring the original paper form by mail or by fax, or by checking the order by calling the doctor. [13] [14] [15] Due to the ease of access to the Internet it is likely that some European consumers use these American or other, illegally practising online pharmacies to purchase drugs. One factor that may direct consumers to favour national drug markets is reimbursement policy, i.e. restriction of reimbursement to national products. As reimbursement of medical expenses falls within the domain of subsidiary, the Commission does not have the competence to harmonize national health insurance policies. 16 According to the Amsterdam Treaty, free movement of people, goods, services and capital is not unconditional and can be restricted to protect public health but not for financial reasons. 16 The European Court of Justice ruled on reimbursement of social security benefits twice, namely the case of Kholl on health care treatment and the case of Decker on purchase of a medical device from abroad. 17, 18 In both cases it was decided that reimbursement is justified if the service/benefit is covered by the national health insurance. The European Court of Justice has not ruled on reimbursement of imported medicines. It is uncertain if the above mentioned preliminary rulings can be applied to pharmaceuticals reimbursement. The aim of the proposed study was to find out how EU countries regulate the import of prescription pharmaceuticals and the delivery of foreign European prescriptions. The hypothesis was that the delivery of foreign prescriptions was restricted to cover orders for certain harmless drugs and clear prescriptions. It was also assumed that the import of pharmaceuticals for personal use was restricted by direct methods, i.e. restrictions on amounts and way of import and by indirect methods i.e. restrictions on reimbursement. It was already known that this was the case in Finland. 19,20
METHODS
We prepared an open questionnaire written in English. The questions for acceptance of non-national prescriptions studied the possibility of a consumer purchasing prescription-only medicines (POMs) from another country when a prescription was attained from a physician in another country. Regulations for delivery of foreign prescriptions, such as the type of authorization by the doctor, the form of prescriptions (e.g. paper, fax, electronic) or the type of disclaimed pharmaceutical were studied. The attitude of EU countries to European-level harmonization of the delivery of foreign European prescriptions was asked. Three questions concerning restrictions on the import of POMs were framed. First, we asked about possible restrictions on the amount of pharmaceuticals imported for personal use. Second, we asked what channels the consumer used to purchase pharmaceuticals, such as personally crossing the boarder or by ordering via post or via Internet. Third, we asked whether or not the pharmaceuticals purchased from abroad are reimbursed. EEA countries outside the EU, Iceland and Norway, were not studied. Besides these questions, respondents were given a chance to freely deliver information which they considered relevant to the subject. The questionnaire was delivered by post, fax or email to the respective medicines authorities of the EU countries during Autumn 2000 -Spring 2001. The questionnaire was first tested by the Finnish National Agency for Medicines, which also gave help in directing the questionnaire to a selected official in the medicines authorities in 10 EU countries. Other respondents of the remaining authorities were identified from the web pages of the respective authority, found from a link page for European medicines authorities. 21 A reminder including the same questionnaire was sent after 4-6 weeks if no response was received. If there was no answer despite the reminder, the questionnaire was sent to the leading medical association in the remaining countries to get the required information.
RESULTS
Answers were received from 11 national medicines authorities of Austria, Denmark, France, Finland, Germany, Greece, Netherlands, Spain and Sweden. In the UK we had to turn to the British Medical Association who guided us to the right authority. Authorities that didn't reply were those in Ireland, Italy, Luxembourg and Portugal. Table 1 shows the authorities from whom answers were received. The quality of the information received varied from one country to another. Some countries like Sweden, France and Finland, gave thorough answers. Finland, Sweden and the UK also indicated that the information could be checked on their web sites.
Restrictions on import of drugs for personal use
Information was often missed when one authority referred some of the questions to another authority, who then did not answer. This happened with a few questions in Sweden and Greece. All answers from Luxembourg were lost for this reason. Summaries of the information received are shown in table 2 and table 3.
Acceptance of foreign prescriptions and harmonization of the delivery of European prescriptions Acceptance of foreign prescriptions was possible in all the countries that answered. Many countries said that they lacked special legislation in this area.
Exceptions were Belgium and the Nordic countries, Denmark, Finland and Sweden, where legislation exists for the delivery of foreign prescriptions. Foreign prescriptions are accepted in the UK if the doctor who issued the prescription was licensed to practice there. In the Nordic countries, Nordic prescriptions (Denmark, Finland, Sweden, Norway and Iceland) are recognized and delivered. All countries said that they did not deliver foreign prescriptions for narcotics, psychotrophic pharmaceuticals or other special products or if the authenticity of a prescription was unsure. This was also the case in Nordic countries. Some countries specified that other special products are not delivered, such as pharmaceuticals for hospital use only; non-authorized pharmaceuticals; prescriptions prescribed more than a year ago or that have been purchased previously. Only paper forms of foreign prescriptions were accepted in all countries. Electronic prescriptions, delivered via conventional means (fax or telephone), or computer communications, were allowed only in Sweden, Denmark and Finland if performed nationally. Most countries considered the harmonization of the delivery of prescriptions impossible at the moment. They gave three main reasons: first, reasons associated with the mutual recognition procedure such as differences in selection, trade names and dosage form; second, differences in reimbursement systems; third, prescriptionrelated reasons such as difficulties in understanding prescriptions in a foreign language and difficulties in recognizing the authenticity of prescriptions.
Import for personal use
Import of POMs for personal use from another EU country was allowed in all countries. However, there were some In most countries, import of pharmaceuticals personally by crossing the border was allowed. France, Sweden and Finland also accepted mail delivery. In Greece and Austria the reimbursement of imported pharmaceuticals was reported to depend on the insurance of the individual. Finland, Denmark and Sweden required the pharmaceutical to be priced in the respective country, and thus, to be available there. In Finland it was required that the product was sold under the same trade name and the same package size.
DISCUSSION
These results indicate that there are still barriers, either direct or indirect, to the free circulation of pharmaceuticals in today's Europe. However, the information gained from the national authorities is insufficient to make close comparisons or to draw final conclusions about barriers between EU countries. First, the method used in the study, an open questionnaire, has some drawbacks: it allows respondents to neglect part or even whole questions. It also carries a risk of misunderstanding the questions. However, with the drawbacks taken into consideration, an open questionnaire was still preferred. The subject has not been studied before and we expected to obtain more information this way. There were several possible ways of arriving at the situation we described concerning the authorization of the doctor and the location of the practice in relation to the country where the patient purchased the prescription and where the patient was in general entitled to reimbursement. We did not separate these. Nor did we provide questions detailing all the differences in the Internal Market concerning the same product, i.e. different trade name, package size, amounts of the active ingredients, sold as POM or over the counter, or marketing authorization or not. By the deliberate use of open questions we hoped that the authorities would indicate how they had regulated these situations. Secondly, we assumed that the selected authorities do not have knowledge of the requirements of other groups. In some cases the required information should have been gained from several authorities. Thirdly, the cultural atmosphere of a country, especially the administrative traditions and procedures, reflect the transparency of authority information. In addition, it is unlikely that the situation in countries that did not answer would be much different. Altogether, the study produced evidence in support of our hypothesis. The first main indication used in the study, the mutual acceptance of prescriptions, is not a reality in every EU country. The Nordic countries and the UK have a legislative framework but the rest of the EU countries seemed to practise according to their national regulations for delivery of national prescriptions. Mutual recognition is hampered by several factors including linguistic barriers (prescription in a foreign language), differences in product names and pharmaceutical selections and difficulties in recognition of foreign doctors. It is understandable that the amounts of imported pharmaceuticals are restricted. It could be difficult to prove that larger amounts of drugs are only for personal use. These restrictions might also be of a protective nature: pharmaceuticals have expiration dates and may be sensitive to storage conditions. Some restrictions may be country specific. For example, Finland restricted the import of buprenorfin some years ago as drug addicts 
Restrictions on import of drugs for personal use
travelled to France for the drug, where it was used in the treatment of drug addiction. The question of reimbursement on prescriptions purchased abroad is interesting, even though it probably applies to only a few. There is a conflict between the principle of subsidiary, i.e. it is up to the individual member state to decide on social security policy, and reimbursement for pharmaceuticals. The few answers received by the study group did not totally reject reimbursement for pharmaceuticals attained abroad, but some conditions had to be fulfilled. It is possible that public health care services have a different, restrictive view compared to insurance companies. The ever-increasing use of e-commerce and telemedicine will make the problems of cross-border reimbursement for medical services and goods even more acute. To our knowledge the authorities approach the use of IT in the delivery of pharmaceuticals in quite a conservative way. At present online pharmacies exist only in a few countries, like the UK and the Netherlands. Electronic prescriptions can be used in Finland and Sweden and Denmark. It is noted that pilot projects on electronic prescriptions are being carried out in several other countries.
In our opinion the use of IT in the delivery of drugs should be favoured. IT could help to prevent errors occurring in the conventional delivery of drugs and in the situations encountered in our study. With IT solutions, doctors, drugs and prescriptions can be authenticated. A good example is e-signatures. With the coming into force of a European Community Directive on e-Signature in July 2001, e-signatures will gain the same legal status as traditional signatures. 22 The role of IT in the delivery of drugs should be defined at European level to prevent malpractice and other IT related problems, as found in the USA. These results indicate that there are still barriers to true circulation of pharmaceuticals in today's EU. This finding is not in line with the principles of the EU single market. As the current situation is quite confusing, we strongly recommend that the EU should seek to solve the problems encountered.
